Risks and benefits associated with novel phase 1 oncology trial designs
Authors:
- Elizabeth Garrett‐MayerEGElizabeth Garrett‐Mayer
- Benjamin KrohmalBKBenjamin Krohmal
- Elizabeth WolfEWElizabeth Wolf
- Cary P. GrossCGCary P. Gross
Open Access
Abstract
BACKGROUND.: Although aggressive dose escalation strategies were designed to improve the risk‐benefit profile of phase 1 oncology trials, they have not been adequately studied. The prevalence of several novel trial designs and their association with a variety of clinical endpoints was evaluated.METHODS.: A review of the literature was performed to identify phase 1 oncology studies of cytotoxic agents published from 2002 through 2004.RESULTS.: Of 955 phase 1 oncology articles initially identified, 149 studies, comprising 4532 patients, were analyzed. Only 34% of studies utilized aggressive dose escalation schemes, 22% permitted intrapatient dose escalation, and only 28% enrolled fewer than 3 patients to any dose level. Studies that allowed intrapatient dose escalation or used fewer than 3 patients per dose were not associated with different rates of response or toxicity, nor did they increase the number of patients who received the recommended phase 2 dose. However, aggressive dose escalations were associated with increased rates of both hematologic (17% vs 10%) and nonhematologic (17% vs 13%) toxicity with similar response rates. Only studies that used conservative dose escalation designs and those that studied U.S. Food and Drug Administration (FDA)‐approved agents required fewer patients to complete a trial. Trials of FDA‐approved agents were also associated with higher response rates than trials of non‐FDA‐approved agents (10% vs 2%), without an increased risk of toxicity.CONCLUSIONS.: Several novel aggressive design strategies intended to improve the risk‐benefit profile of phase 1 oncology trials are not associated with improved clinical outcome, and may be harmful in certain instances. Cancer 2007. Published 2007 American Cancer Society.Keywords
This publication has 35 references indexed in Scilit:
- Measures of Response: RECIST, WHO, and New AlternativesJournal of Clinical Oncology, 2006
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002New England Journal of Medicine, 2005
- Risks and Benefits of Phase 1 Oncology Trials, RevisitedNew England Journal of Medicine, 2005
- Dose‐Finding Based on Efficacy–Toxicity Trade‐OffsBiometrics, 2004
- Descriptions of Benefits and Risks in Consent Forms for Phase 1 Oncology TrialsNew England Journal of Medicine, 2002
- Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancerStatistics in Medicine, 2002
- Quality of informed consent in cancer clinical trials: a cross-sectional surveyThe Lancet, 2001
- Phase I trial design: Are new methodologies being put into practice?Annals of Oncology, 1996
- Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer AgentsJNCI: Journal of the National Cancer Institute, 1993
- Model-Guided Determination of Maximum Tolerated Dose in Phase I Clinical Trials: Evidence for Increased PrecisionJNCI: Journal of the National Cancer Institute, 1993